Oryzon Genomics - Multiple data readouts in 2019 within cash reach
Oryzon is ramping up its R&D programme and plans to conduct a total of four mid-stage clinical trials with lead assets ORY-1001 (a specific LSD1 inhibitor for cancers) and ORY-2001 (a dual LSD1/MAOB inhibitor for CNS indications). If all goes according to plan, data readouts are expected from all four trials in 2019 and these key catalysts are reachable with current cash, as per our calculations. The most advanced studies are the two Phase IIa trials with ORY-2001 in multiple sclerosis (MS) and Alzheimer’s disease with the MS study, SATEEN, enrolling patients since January 2018. Our valuation is marginally higher at €315m or €9.2/share.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.